اخبار و اعلانات

 آمار

تعداد نشریات284
تعداد نشریات سازمان82
تعداد شماره‌ها3,048
تعداد مقالات34,077
تعداد مشاهده مقاله46,504,330
تعداد دریافت فایل اصل مقاله77,558,934
Adnan Mezher, M, Bahjat Alrifai, S, Mahmood Raoof, W. (1401). Analysis of Proinflammatory Cytokines in COVID-19 Patients in Baghdad, Iraq. سامانه مدیریت نشریات علمی, 78(1), 305-313. doi: 10.22092/ari.2022.359356.2411
M Adnan Mezher; S Bahjat Alrifai; W Mahmood Raoof. "Analysis of Proinflammatory Cytokines in COVID-19 Patients in Baghdad, Iraq". سامانه مدیریت نشریات علمی, 78, 1, 1401, 305-313. doi: 10.22092/ari.2022.359356.2411
Adnan Mezher, M, Bahjat Alrifai, S, Mahmood Raoof, W. (1401). 'Analysis of Proinflammatory Cytokines in COVID-19 Patients in Baghdad, Iraq', سامانه مدیریت نشریات علمی, 78(1), pp. 305-313. doi: 10.22092/ari.2022.359356.2411
Adnan Mezher, M, Bahjat Alrifai, S, Mahmood Raoof, W. Analysis of Proinflammatory Cytokines in COVID-19 Patients in Baghdad, Iraq. سامانه مدیریت نشریات علمی, 1401; 78(1): 305-313. doi: 10.22092/ari.2022.359356.2411

Analysis of Proinflammatory Cytokines in COVID-19 Patients in Baghdad, Iraq

Archives of Razi Institute
مقاله 39، دوره 78، شماره 1، فروردین و اردیبهشت 2023، صفحه 305-313    اصل مقاله (662.14 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.359356.2411
نویسندگان
M Adnan Mezher* 1؛ S Bahjat Alrifai2؛ W Mahmood Raoof1
1Collage of Pharmacy, Tikrit University, Tikrit, Iraq
2Collage of Medicine, Ibn Sina University of Medical and Pharmaceutical Science, Baghdad, Iraq
چکیده
Due to the pandemic of COVID -19 disease and the fact that the effective variables in the severity and control of the disease have not been established, numerous factors have been investigated, including the study of inflammatory factors. A cross-sectional study was carried out to investigate the proinflammatory cytokines in patients with COVID -19, conducted in Baghdad, Iraq. The age of the patients was above > (15) years old, with confirmed infection documented by polymerase chain reaction (PCR). The subjects were 132 patients, 69 (52.3%) males, and 63 (47.7%) females. Patients were divided into three pathological groups: mild patients (45), moderate patients (34), and severe patients (53), each group was divided into four weeks according to symptoms onset date. The most common clinical symptoms were cough, fever, and headache, while sore throat, gastrointestinal symptoms, chest pain, and loss of taste and smell were less common in COVID -19 patients. Sandwich-Enzyme-Linked Immunosorbent Assay kits were used to evaluate levels of proinflammatory cytokines, including IL-1β, IL-6, IL-8, and TNF-α. The results IL-6 and TNF-α were significantly elevated in mild during the four weeks with (P=0.0071) and (0.0266) respectively, levels of IL-1β were increased with highly significant differences (P=0.0001) while levels of IL-8 were decreased with highly significant differences (P=0.0001) during the four weeks. In moderate patients, levels of (IL-1β, IL-6, and IL-8) increased without significance (P=0.661, 0.074, 0.0651), respectively; in contrast, the levels of TNF-α increased with significant (P=0.0452) across four weeks. Severe COVID-19 patients showed significantly increased differences in levels of (IL-6, IL-8, and TNFα) (P=0.0438, 0.0348, 0.0447), respectively, while no significant differences in the level of IL-1β (P=0.0774). This study showed that investigating inflammatory factors in the COVID-19 pandemic is crucial in controlling and treating.
کلیدواژه‌ها
Covid-19؛ Proinflammatory cytokines؛ IL-1β؛ IL-6؛ IL- 8؛ TNF-α
سایر فایل های مرتبط با مقاله
مراجع
  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020.
  2. Cron RQ, Behrens EM. Cytokine storm syndrome: Springer; 2019.
  3. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.
  4. Takeuchi O. Posttranscriptional regulation of cytokine mRNA controls the initiation and resolution of inflammation. Chronic Inflammation: Springer; 2016. p. 319-32.
  5. Chauhan P, Nair A, Patidar A, Dandapat J, Sarkar A, Saha B. A primer on cytokines. Cytokine. 2021;145:155458.
  6. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773-89.
  7. SAS J. Statistical Analysis System, v. 10.0. 2. Cary, North Carolina USA. 2012.
  8. Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RW, et al. Longitudinal cytokine profile in patients with mild to critical COVID-19. Front Immunol. 2021;12.
  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
  10. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.
  11. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020;382(24):2372-4.
  12. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-33.
  13. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;56(3):308-21.
  14. Bartz D, Chitnis T, Kaiser UB, Rich-Edwards JW, Rexrode KM, Pennell PB, et al. Clinical advances in sex-and gender-informed medicine to improve the health of all: a review. JAMA Intern Med. 2020;180(4):574-83.
  15. Raimondi F, Novelli L, Ghirardi A, Russo FM, Pellegrini D, Biza R, et al. Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study. BMC Pulm Med. 2021;21(1):1-11.
  16. Knowlton AA, Lee A. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135(1):54-70.
  17. Killerby ME, Link-Gelles R, Haight SC, Schrodt CA, England L, Gomes DJ, et al. Characteristics associated with hospitalization among patients with COVID-19—Metropolitan Atlanta, Georgia, March–April 2020. Morb Mortal Wkly Rep. 2020;69(25):790.
  18. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020.
  19. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
  20. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41.
  21. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino L. 2020;277(8):2251-61.
  22. Zeng Z, Yu H, Chen H, Qi W, Chen L, Chen G, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Critic Care. 2020;24(1):1-12.
  23. Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, et al. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. Sci Rep. 2020;10(1):1-11.
  24. Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, et al. Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. Immun Ageing. 2022;19(1):1-17.
  25. Tan Y, Zhang W, Zhu Z, Qiao N, Ling Y, Guo M, et al. Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. Cell Discov. 2021;7(1):1-19.
  26. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14(5):315-28.
  27. Ye Q, Wang B, Mao J. The pathogenesis and treatment of theCytokine Storm'in COVID-19. J infect. 2020;80(6):607-13.
  28. Min C-K, Cheon S, Ha N-Y, Sohn KM, Kim Y, Aigerim A, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6(1):1-12.
  29. Rodrigues TS, de Sá KS, Ishimoto AY, Becerra A, Oliveira S, Almeida L, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3).
  30. Jurado A, Martín MC, Abad-Molina C, Orduña A, Martínez A, Ocaña E, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;17(1):1-15.
  31. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671-92.
  32. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-24.
  33. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-44.
  1. Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406-15.
آمار
تعداد مشاهده مقاله: 2,552
تعداد دریافت فایل اصل مقاله: 6,051


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب